Brief: Atea Pharmaceuticals Reports First Quarter 2023 Financial Results And Provides Business Update
08/05/2023 23:32
May 8 (Reuters) - Atea Pharmaceuticals Inc AVIR.O :
* ATEA PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE
* ATEA - PHASE 2 TRIAL EVALUATING COMBINATION OF
BEMNIFOSBUVIR &
RUZASVIR ON TRACK FOR FIRST PATIENT DOSED 2Q23; INITIAL RESULTS
EXPECTED IN 4Q23
* QTRLY LOSS PER SHARE $0.43
* Q1 EARNINGS PER SHARE VIEW $-0.48 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX6hdHXK
Further company coverage: AVIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM